...
首页> 外文期刊>Neuropsychiatric Disease and Treatment >Clinical feature and outcome of late-onset cobalamin C disease patients with neuropsychiatric presentations: a Chinese case series
【24h】

Clinical feature and outcome of late-onset cobalamin C disease patients with neuropsychiatric presentations: a Chinese case series

机译:迟发性钴胺素C病患者神经精神病学表现的临床特征和预后:中国病例系列

获取原文

摘要

Objective: The Cobalamin C (cblC) disease is an inborn error of cobalamin metabolism. Late-onset cblC disease was diagnosed in patients having overt symptoms after 4 years of age. The late-onset cblC disease patients were rare and easily misdiagnosed. This study analyzed the clinical presentations, gene mutations, and treatments of Chinese patients with late-onset cblC disease. Methods: The clinical data of 26 Han Chinese patients diagnosed with late-onset cblC disease were retrospectively analyzed. All patients underwent serum homocysteine level exam, urine concentrations of organic acids measurement, neuroimaging scans, gene analysis, and treatments evaluations. Results: The mean age at disease onset and diagnosis was 17.8±7.0 years. The most frequent neuropsychiatric disturbances were lower limb weakness (50%), psychiatric disturbances (46.2%), and gait instability (42.3%). The mean methylmalonic acid level in urine was 107.4±56.6 μmol/L, and mean serum total homocysteine was 105.4±41.0 μmol/L. The most common abnormal radioimaging changes were observed in the spinal cord (88%) and brain (32%). Scoliosis was detected in 85.7% of patients. The methylmalonic aciduria and homocystinuria type C protein gene analysis showed that c.482GA (57.7%) and c.609GA (34.6%) mutations were the most frequent genotypes. After treatments with hydroxycobalamin, betaine, folic acid, L-carnitine, and compound vitamin B, the clinical features and biochemical parameters of patients with late-onset cblC disease were found to be alleviated. Conclusion: In our late-onset cblC disease cases, lower limb weakness, psychiatric disturbances, and gait instability were the most frequent manifestations. Patients responded well to the drug treatments with hydrocobalamin and betaine. When juvenile or adult patients with hyperhomocysteinemia present with neurological symptoms, cblC disease needs to be considered.
机译:目的:钴胺素C(cblC)疾病是钴胺素代谢的先天性错误。在4岁后出现明显症状的患者中诊断为迟发性cblC疾病。迟发性cblC病患者很少见,容易被误诊。这项研究分析了中国迟发性cblC病患者的临床表现,基因突变和治疗方法。方法:回顾性分析26例确诊为迟发性cblC疾病的汉族患者的临床资料。所有患者均接受血清高半胱氨酸水平检查,尿液中有机酸浓度测量,神经影像扫描,基因分析和治疗评估。结果:发病和诊断的平均年龄为17.8±7.0岁。最常见的神经精神障碍是下肢无力(50%),精神障碍(46.2%)和步态不稳(42.3%)。尿液中的甲基丙二酸平均水平为107.4±56.6μmol/ L,平均血清总同型半胱氨酸为105.4±41.0μmol/ L。在脊髓(88%)和大脑(32%)中观察到最常见的异常放射成像变化。在85.7%的患者中发现了脊柱侧弯。甲基丙二酸尿症和高半胱氨酸尿症的C型蛋白基因分析表明,c.482G> A(57.7%)和c.609G> A(34.6%)突变是最常见的基因型。用羟基钴胺素,甜菜碱,叶酸,左旋肉碱和复合维生素B治疗后,发现迟发性cblC病患者的临床特征和生化指标得到缓解。结论:在我们的迟发性cblC疾病病例中,下肢无力,精神障碍和步态不稳是最常见的表现。患者对氢钴胺素和甜菜碱的药物治疗反应良好。当高同型半胱氨酸血症的青少年或成人患者出现神经系统症状时,需要考虑cblC疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号